dm-1

Mertansine is a tubulin inhibitor and an antibody-conjugable maytansinoid alkaloid. The IC50 of Mertansine against HCT-15 and A431 cells is 0.750 and 0.04nM.

Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody–drug conjugate that combines the HER2-targeted antitumor specificity of trastuzumab with the potent cytotoxic activity of the microtubule inhibitor DM1, Trastuzumab emtansine enables selective intracellular delivery of the cytotoxic payload to HER2-expressing cells and supporting translational and mechanistic research in advanced breast cancer models.

Lys-SMCC-DM1 (Lys-Nε-MCC-DM1) is an antibody-drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2). It contains the microtubule polymerization inhibitor DM1 as the active metabolite, which inhibits microtubule polymerization. It is commonly used in breast cancer research.

S-methyl DM1, a thiomethyl derivative of Maytansine, binds to tubulin (Kd of 0.93 μM) and inhibits microtubule polymerization.

SMCC-DM1 is a drug-coupler coupler consisting of a potent microtubule disrupter, DM1, and a coupler, SMCC, for the preparation of antibody-drug couplers.

DM1-(PEG)4-DBCO is a drug-linker conjugate that combines the potent microtubulin inhibitor mertansine (DM1) with the DBCO-PEG4-Ahx linker for developing antibody-drug conjugates (ADCs). This conjugation aims to mitigate systemic toxicity associated with maytansine while improving tumor-specific delivery, leveraging DM1's ability as an antibody-conjugatable maytansinoid.

Mal-VC-PAB-DM1, a drug-linker conjugate for antibody-drug conjugates (ADCs), exhibits potent antitumor activity. It incorporates DM1, a potent microtubule-disrupting agent, connected through the ADC linker Mal-VC-PAB [1].

SC-VC-PAB-DM1 is a drug-linker conjugate used in Antibody-Drug Conjugates (ADC), combining DM1 (Mertansine, a tubulin inhibitor) with the SC-VC-PAB[1] ADC linker to deliver potent antitumor activity.

SPP-DM1, a drug-linker conjugate for antibody-drug conjugates (ADC), demonstrates potent antitumor activity. It comprises DM1 (a potent microtubule-disrupting agent) connected through the ADC linker SPP[1].

DM1-SMe (DM1-SSMe) is a potent inhibitor of maytansinoid microtubular. DM1-SMe is about 3 to 10-fold more potent than the parent drug Maytansine, with IC50s of 0.003 to 0.01 nM for DM1-SMe in a panel of human tumor cell lines.

DM1-MCC (MCC-DM1) is an anticancer drug DM1 with an MCC linker.

MCC-DM1 is a drug-Linker Conjugates for ADC such ad Anti-CD22-MCC-DM1.

MC-DM1 is a drug-linker conjugate composed of a potent microtubule-disrupting agent DM1 and a linker MC to make antibody drug conjugate (ADC).

DBCO-PEG4-Ahx-DM1 is a drug-linker conjugate that combines the microtubulin inhibitor DM1 (mertansine), an antibody-conjugatable maytansinoid designed to reduce systemic toxicity and improve tumor-specific delivery, with the linker DBCO-PEG4-Ahx, for developing antibody drug conjugates (ADCs).

SPDB-DM4 is a part of the ADC. It is composed of DM1 (a microtubule inhibitor, also an antibody-encodable aristolochic acid alkaloid, used to overcome the systemic toxicity associated with aristolochic acid and enhance tumor-specific delivery) and SPDB, and exhibits highly efficient anti-tumor activity.

MPB-VC-PAB-DM1 is a thiol-reactive Drug-linker. DM1 is a microtubule inhibitor, which is commonly used in the synthesis of antibody-drug conjugates (ADCs).

MC-ADAA-S-NCA-DM1 is a thiol-reactive Drug-linker. DM1 is a microtubule inhibitor, which is commonly used in the synthesis of antibody-drug conjugates (ADCs).

DBCO-PEG4-VC-PAB-Ahx-DM1 is a click-reactive Drug-linker that contains a DBCO group and can undergo strain-promoted acetylene-nitride cycloaddition reaction (SPAAC) with molecules containing Azide groups. DM1 is a microtubule protein inhibitor. DBCO-PEG4-VC-PAB-Ahx-DM1 can be used in the synthesis of antibody-drug conjugates (ADCs).

Gly5-Ahx-DM1 is a transpeptidase reaction-type Drug-linker with an innovative highly stable and degradable linker. DM1 is a microtubulin inhibitor and can be used in the synthesis of antibody-drug conjugates (ADCs).

Ahx-DM1 (compound 2A) is a conjugate of proteins/peptides that can be combined with therapeutic, diagnostic, or labeling agents.

Ahx-DM1 (TFA) (compound 2A) is a conjugate of proteins/peptides that can combine with therapeutic, diagnostic, or labeling agents.

BrAc-Galactose-Sar-N-Me-alanine-DM1 (compound 11) is an integral part of an antibody-drug conjugate (ADC) as a drug-linker conjugate. It can be conjugated with anti-TM4SF1 antibodies, such as AGX-A07, for the synthesis of ADCs.

vc-PABC-DM1 is a chemical compound utilized for the synthesis of an antibody-drug conjugate (ADC) that incorporates a disulfide linker. This compound is instrumental in investigating serum stability [1].

(Rac)-Lys-SMCC-DM1 ((Rac)-Lys-Nε-MCC-DM1) is the racemic form of Lys-SMCC-DM1, which serves as a linker-payload component capable of inhibiting tubulin polymerization. It is also recognized as the active metabolite of T-DM1 [1].